A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion

Pharmacogenomics Journal

Volumn 11, Issue 3, 2011, Pages 191-198

  Kim, I ^a,b   Kang, E S ^a   Yim, Y S ^a   Ko, S J ^a   Jeong, S H ^a   Rim, J H ^a   Kim, Y S ^c   Ahn, C W ^a   Cha, B S ^a   Lee, H C ^a   Kim, C H ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Korea National Institute of Health   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

cyclosporin A; insulin; polymorphism; post transplantation diabetes mellitus; zinc transporter 8

Indexed keywords

CYCLOSPORIN A; DOWN SYNDROME CANDIDATE REGION 1 PROTEIN; MEMBRANE PROTEIN; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; ZINC ION; ZINC TRANSPORTER; ZINC TRANSPORTER 8;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EXOCYTOSIS; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; INSULIN DEFICIENCY; INSULIN RELEASE; MARKER GENE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; SLC30A8 GENE;

ALLELES; ANIMALS; BIOMARKERS, PHARMACOLOGICAL; CALCINEURIN; CATION TRANSPORT PROTEINS; CELL LINE; CYCLOSPORINE; DIABETES MELLITUS; GLUCOSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY TRANSPLANTATION; MICE; MUSCLE PROTEINS; MUTATION; RATS;

EID: 79957515571     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.22     Document Type: Article

References (37)

1. First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Posttrans-plant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002; 73: 379-386. (Pubitemid 34174287)
2. Ducloux D, Kazory A, Chalopin JM. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 2005; 79: 438-443. (Pubitemid 40280176)
3. Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588-595. (Pubitemid 43164454)
4. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 1331-1336. (Pubitemid 46871653)
5. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445: 881-885.
6. Lyssenko V, Groop L. Genome-wide association study for type 2 diabetes: clinical applications. Curr Opin Lipidol 2009; 20: 87-91.
7. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 2004; 53: 2330-2337. (Pubitemid 39145586)
8. Kang ES, Kim MS, Kim YS, Kim CH, Han SJ, Chun SW et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 2008; 57: 1043-1047.
9. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001; 71: 1417-1423. (Pubitemid 32507115)
10. Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007; 30: 609-615.
11. Pound LD, Sarkar S, Benninger RK, Wang Y, Suwanichkul A, Shadoan MK et al. Deletion of the mouse Slc30a8 gene encoding zinc transporter-8 results in impaired insulin secretion. Biochem J 2009; 421: 371-376.
12. Mocchegiani E, Giacconi R, Malavolta M. Zinc signalling and subcellular distribution: emerging targets in type 2 diabetes. Trends Mol Med 2008; 14: 419-428.
13. Chimienti F, Devergnas S, Pattou F, Schuit F, Garcia-Cuenca R, Vandewalle B et al. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sci 2006; 119(Pt 20): 4199-4206. (Pubitemid 44774026)
14. Fu Y, Tian W, Pratt EB, Dirling LB, Shyng SL, Meshul CK et al. Down-regulation of ZnT8 expression in INS-1 rat pancreatic beta cells reduces insulin content and glucose-inducible insulin secretion. PLoS One 2009; 4: e5679.
15. Lawrence MC, Bhatt HS, Watterson JM, Easom RA. Regulation of insulin gene transcription by a Ca(2+)-responsive pathway involving calcineur-in and nuclear factor of activated T cells. Mol Endocrinol 2001; 15: 1758-1767. (Pubitemid 32939306)
16. Heit JJ. Calcineurin/NFAT signaling in the beta-cell: from diabetes to new therapeutics. Bioessays 2007; 29: 1011-1021. (Pubitemid 47522841)
17. Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 2003; 55: 105-131. (Pubitemid 36268400)
18. Donelan MJ, Morfini G, Julyan R, Sommers S, Hays L, Kajio H et al. Ca2+-dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells. Implications for regulated beta-granule transport and insulin exocytosis. J Biol Chem 2002; 277: 24232-24242. (Pubitemid 34951940)
19. Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crabtree GR et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006; 443: 345-349. (Pubitemid 44435154)
20. Borlak J, Niehof M. HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus. PLoS One 2009; 4: e4662.
21. Robertson RP. Cyclosporin-induced inhibition of insulin secretion in isolated rat islets and HIT cells. Diabetes 1986; 35: 1016-1019. (Pubitemid 16029822)
22. Teuscher AU, Seaquist ER, Robertson RP. Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes 1994; 43: 593-598. (Pubitemid 24096302)
23. Kambe T, Narita H, Yamaguchi-Iwai Y, Hirose J, Amano T, Sugiura N et al. Cloning and characterization of a novel mammalian zinc transporter, zinc transporter 5, abundantly expressed in pancreatic beta cells. J Biol Chem 2002; 277: 19049-19055. (Pubitemid 34952469)
24. Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 2004; 145: 667-678. (Pubitemid 38183809)
25. Nicolson TJ, Bellomo EA, Wijesekara N, Loder MK, Baldwin JM, Gyulkhandanyan AV et al. Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. Diabetes 2009; 58: 2070-2083.
26. Zhang N, Su D, Qu S, Tse T, Bottino R, Balamurugan AN et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006; 55: 2429-2436. (Pubitemid 44871142)
27. Chan B, Greenan G, McKeon F, Ellenberger T. Identification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 13075-13080. (Pubitemid 41324981)
28. Kim YS, Cho KO, Lee HJ, Kim SY, Sato Y, Cho YJ. Down syndrome candidate region 1 increases the stability of the IkappaBalpha protein: implications for its anti-inflammatory effects. J Biol Chem 2006; 281: 39051-39061. (Pubitemid 46041864)
29. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59: 732-737. (Pubitemid 32157939)
30. Hjelmesaeth J, Asberg A, Muller F, Hartmann A, Jenssen T. New-onset posttransplantation diabetes mellitus: insulin resistance or insulinope-nia? Impact of immunosuppressive drugs, cytomegalovirus and hepatitis C virus infection. Curr Diabetes Rev 2005; 1: 1-10.
31. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008; 57: 945-957.
32. Rodrigo E, Fernandez-Fresnedo G, Valero R, Ruiz JC, Pinera C, Palomar R et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol 2006; 17(12 Suppl 3): S291-S295. (Pubitemid 44865264)
33. Veroux M, Corona D, Giuffrida G, Gagliano M, Sorbello M, Virgilio C et al. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant Proc 2008; 40: 1885-1887.
34. Shimodahira M, Fujimoto S, Mukai E, Nakamura Y, Nishi Y, Sasaki M et al. Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism. J Endocrinol 2010; 204: 37-46.
35. Sulanc E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation 2005; 80: 945-952. (Pubitemid 41552891)
36. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185. (Pubitemid 36323115)
37. International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-796.